Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT
in combination with apalutamide as an adjuvant regimen for patients with high risk of
recurrence after radical prostatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School